Latest Articles

Publication Date
Anti-NRP1 peptide-engineered ROS/pH dual-responsive nanoparticles for Alpelisib delivery regulate Sema3A-NRP1/PI3K-AKT signaling to balance oxidative stress and inhibit angiogenesis in endometriosis.

Endometriosis progression is driven by oxidative stress and excessive angiogenesis within an inflammatory microenvironment. To overcome these challenges, we designed ROS/pH dual-responsive Alpelisib-loaded nanoparticles (Alp@TAT-AT7-NPs) functionalized with an anti-NRP1 peptide …

Published: June 6, 2026, midnight
Women ‘blindsided’ as critical hormone therapy pulled from shelves - Herald Sun

Women ‘blindsided’ as critical hormone therapy pulled from shelves Herald Sun

Published: June 4, 2026, 8:38 p.m.
FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion - TradingView

FOCL: Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion TradingView

Published: June 4, 2026, 7:18 p.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - NT News

Women ‘blindsided’ as critical hormone therapy pulled from shelves NT News

Published: June 4, 2026, 4:21 a.m.
Women ‘blindsided’ as critical hormone therapy pulled from shelves - The Cairns Post

Women ‘blindsided’ as critical hormone therapy pulled from shelves The Cairns Post

Published: June 4, 2026, 4:20 a.m.
Psychological flexibility and pain catastrophizing in endometriosis: Incremental validity and interaction effects in predicting psychosocial outcomes.

Psychological distress and reduced health-related quality of life are common among women with endometriosis, particularly when the condition is accompanied by chronic pain. Psychological flexibility (PF), a core process in …

Published: June 4, 2026, midnight
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post

Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post

Published: June 3, 2026, 2:49 p.m.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily

NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily

Published: June 3, 2026, 3:15 a.m.
MGST3 Promotes Endometriosis Progression by Suppressing Ferroptosis.

Endometriosis (EMs) is characterized by dysregulated persistence and enhanced invasiveness of ectopic endometrial cells. Current treatment strategies remain limited by high recurrence rates and considerable adverse effects. Although iron overload …

Published: June 3, 2026, midnight
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!